Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: A preliminary report

Journal of Viral Hepatitis

Volumn 3, Issue 1, 1996, Pages 37-42

  Hourvitz, A ^a   Mosseri, R ^a   Solomon, A ^a   Yehezkelli, Y ^a   Atsmon, J ^a   Danon, Y L ^d   Koren, R ^b   Shouval, D ^c  

^a MEDICAL CORPS   (Israel)

^b Research Division   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d NONE

Author keywords

Hepatitis B; Mammalian cell vaccine; Pre S proteins

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HAMSTER; HEPATITIS B; HUMAN; IMMUNOLOGY; MALE; PHASE 1 CLINICAL TRIAL; SEX;

ADOLESCENT; ADULT; ANIMALS; ANTIBODY FORMATION; CHO CELLS; CRICETINAE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; SEX; VACCINES, SYNTHETIC;

EID: 0029687236     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00079.x     Document Type: Article

References (21)

1. Szmuness W, Stevens CE, Sang EA et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology 1981; 1: 377-385.
2. Maupas P, Goudeau A, Coursaget P, Bagtrol P. Immunization against hepatitis B in man. Lancet 1976; i: 1367-1370.
3. McAleer WJ, Buynak EB, Maigetter EZ et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-181.
4. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8: 574-578.
5. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13 (A): 39-45.
6. Even-Chen Z, Drummer H, Levanon A, Panet A, Gorecki M. Development of a novel hepatitis B vaccine containing Pre S1. In: White MD, Reuveny S, Shafferman A, eds. Biologicals from Recombinant Microorganisms and Animal Cells. Germany: VCH Weinheim, 1990: 533-546.
7. Milich DR, Thornton GB, Neurath AR et al. Enhanced immunogenicity of the Pre S region of hepatitis B surface antigen. Science 1985; 228: 1195-1198.
8. Milich DR, McLachlan A, Chisari FV, Kent SBH, Thornton GB. Immune response to the Pre S1 region of the hepatitis B surface antigen (HBsAg). J Immunol 1986; 137: 315-322.
9. Gerlich DH, Deepen R, Heermann KH et al. Protection potential of hepatitis B virus antigens other than the S gene protein. Vaccine 1990; 8: S63-S68.
10. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein - a preliminary study on immunogenicity. Vaccine 1992; 10: 439-442.
11. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE. eds. Viral Hepatitis. Philadelphia: Franklin Institute Press 1982; 451-466.
12. Shouval D, Ilan Y, Adler R et al. Improved immunogenicity in mice of a recombinant hepatitis B vaccine containing Pre S1 and Pre S2 antigens in HBs particles (Abstr) J Hepatol 1991; 13: 871.
13. Shouval D, Ilan Y, Adler R et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing Pre S1 and Pre S2 antigens as compared to conventional yeast-derived vaccines. Vaccine 1994; 12: 1453-1459.
14. Milich DR, Thornton GB. Cell recognition of hepatitis B viral antigens. Immunol Today 1988; 9: 380-391.
15. Alper CA, Kruskall MS, MarcusOBagley D et al. Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med 1989; 321: 708-712.
16. Craven DE, Awdeh ZL, Kunches LM et al. Non-responsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med 1986; 105: 356-360.
17. Budkowska A, Dubrevil P, Capel F, Pillot J. Hepatitis B virus Pre-S gene-encoded antigenic specificity and anti-Pre S antibody: relationship between anti-Pre S response and recovery. Hepatology 1986; 6: 360-368.
18. Ellis RW, Kniskern PJ, Arpi H et al. Preparation and testing of a recombinant-derived hepatitis B vaccine consisting of Pre S2 + S polypeptides. In: Zuckerman AZ, ed. Hepatitis and Liver Disease. New York: Alan R. Liss, 1987; 1079-1082.
19. Coursaget P, Bringer L, Sarv G et al. Comparative immunology in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine. Vaccine 1992; 10: 379-382.
20. Cupps TR, Tibbies J, Hurni WM, Miller WJ, Ellis RW, Milich D, Wetter N. In vitro T cell immune response to the Pre-S2 antigen of the hepatitis B virus envelope protein in Pre-S2 + S vaccine recipients. J Immunol 1993; 151: 3353-3360.
21. Shouval D, Ilan Y, Hourvitz A et al. Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing Pre S2 and Pre S1 antigens: a preliminary report. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Proceedings of the International Symposium on Viral Hepatitis and Liver Disease (8th Triennial Congress). Springer, Tokyo, 1994; pp. 543-546.